Skip to main content

Drug Interactions between fecal microbiota, live and Lorabid Pulvules

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

loracarbef fecal microbiota, live

Applies to: Lorabid Pulvules (loracarbef) and fecal microbiota, live

ADJUST DOSING INTERVAL: Antibiotics may interfere with the therapeutic effects of fecal microbiota, which contains live bacteria. The mechanism may be related to the antibiotic inactivating the bacteria or reducing bacterial replication. In clinical studies an antibiotic washout period between 24 to 72 hours was required prior to the rectal administration of fecal microbiota.

MANAGEMENT: Although data are limited, it may be prudent to have an antibiotic washout period between 24 to 72 hours prior to administration of the rectal formulation of fecal microbiota. In addition, the manufacturer recommends avoiding oral antibiotics for up to 8 weeks after administration of the rectal formulation of fecal microbiota.

References (2)
  1. (2022) "Product Information. Rebyota (fecal microbiota, live)." Ferring Pharmaceuticals Inc
  2. singh p, Alm EJ, Kelley JM, Cheng V, Smith M, Kassam Z, Nee J, Iturrino J, Lembo A (2022) "Effect of antibiotic pretreatment on bacterial engraftment after Fecal Microbiota Transplant (FMT) in IBS-D" National Library of Medicine, 14, p. 1

Drug and food interactions

Moderate

loracarbef food

Applies to: Lorabid Pulvules (loracarbef)

ADJUST DOSING INTERVAL: Loracarbef may exhibit reduced gastrointestinal absorption in the presence of food. When loracarbef capsules were administered with food, the peak plasma concentrations were 50% to 60% of concentrations after administration in a fasting state and were reached 30 to 60 minutes later. Area under the concentration-time curve (AUC) was not affected. The therapeutic effect of the antimicrobial may be reduced.

MANAGEMENT: Loracarbef should be administered at least one hour before or two hours after eating.

References (1)
  1. (2002) "Product Information. Lorabid (loracarbef)." Lilly, Eli and Company

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer